Viral hepatitis prevalence in patients with active and latent tuberculosis

World Journal of Gastroenterology

Volumn 21, Issue 29, 2015, Pages 8974-8980

  Nooredinvand, Hesam Ahmadi ^a   Connell, David W ^a   Asgheddi, Mahmoud ^a   Abdullah, Mohammed ^a   O'Donoghue, Marie ^a   Campbell, Louise ^a   Wickremasinghe, Melissa ^a   Lalvani, Ajit ^a   Kon, Onn Min ^a   Khan, Shahid A ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Drug induced liver injury; Epidemiology; Hepatitis B; Hepatitis C; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ETHAMBUTOL; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; PYRIDOXINE; BIOLOGICAL MARKER; TUBERCULOSTATIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PREVALENCE; RASH; RISK ASSESSMENT; SCREENING; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; VOMITING; ADOLESCENT; BLOOD; CHEMICAL AND DRUG INDUCED LIVER INJURY; MASS SCREENING; MIDDLE AGED; MIXED INFECTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BIOMARKERS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COINFECTION; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; LATENT TUBERCULOSIS; LIVER FUNCTION TESTS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

EID: 84939825856     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i29.8920     Document Type: Article

References (30)

1. World Health Organisation. Global Tuberculosis Control 2011. Date last accessed: 2012 Sept 28. Available from: URL: http:// www.who.int/tb/publications/global-report/en/
2. Health Protection Agency. Tuberculosis in the United Kingdom: Annual report on tuberculosis surveillance in the United Kingdom 2013. Available from: URL: http://www.hpa.org.uk/Publications/ InfectiousDiseases/Tuberculosis/1011TuberculosisintheUK/
3. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008; 14: 6774-6785 [PMID: 19058303 DOI: 10.3748/wjg.14.6774]
4. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202 [PMID: 17995946 DOI: 10.1111/j.1440-1746.2007.05207.x]
5. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477 [PMID: 12569078 DOI: 10.1164/rccm.200206-626OC]
6. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919 [PMID: 12359646 DOI: 10.1164/rccm.2108091]
7. World Health Organisation. Hepatitis B Fact Sheet No. 204. Date last updated: 2012 July. Date last accessed: 2012 Sept 28. Available from: URL: http://www.who.int/mediacentre/factsheets/ fs204/en/
8. World Health Organisation. Global Alert and Response: Hepatitis B. 2002. Date last accessed: 2012 Sept 28. Available from: URL: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/ index.html
9. World Health Organisation. Prevention and Control of Viral Hepatitis: Framework for Global Action 2012. Available from: URL: http://www.who.int/csr/disease/hepatitis/GHP-framework.pdf
10. Health Protection Agency Centre for Infections. Hepatitis C in the United Kingdom: 2011 report. Date last accessed: 2012 Sept 28. Available from: URL: http://www.hpa.org.uk/Publications/Infectious-Diseases/BloodBorneInfections/HepatitisCInTheUnitedKingdom/ 1107HepCintheUnitedKingdom2011report/
11. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]
12. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242 [PMID: 19054588 DOI: 10.1016/ j.jhep.2008.10.001]
13. Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97: 1198-1203 [PMID: 12014728 DOI: 10.1111/j.1572-0241.2002.05704.x]
14. Kuniholm MH, Mark J, Aladashvili M, Shubladze N, Khechinashvili G, Tsertsvadze T, del Rio C, Nelson KE. Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients. Int J Infect Dis 2008; 12: 51-56 [PMID: 17644020 DOI: 10.1016/j.ijid.2007.04.015]
15. Blal CA, Passos SR, Horn C, Georg I, Bonecini-Almeida MG, Rolla VC, De Castro L. High prevalence of hepatitis B virus infection among tuberculosis patients with and without HIV in Rio de Janeiro, Brazil. Eur J Clin Microbiol Infect Dis 2005; 24: 41-43 [PMID: 15616838 DOI: 10.1007/s10096-004-1272-8]
16. Sirinak C, Kittikraisak W, Pinjeesekikul D, Charusuntonsri P, Luanloed P, Srisuwanvilai LO, Nateniyom S, Akksilp S, Likanonsakul S, Sattayawuthipong W, Burapat C, Varma JK. Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Public Health 2008; 8: 245 [PMID: 18638392 DOI: 10.1186/1471-2458-8-245]
17. Aires RS, Matos MA, Lopes CL, Teles SA, Kozlowski AG, Silva AM, Filho JA, Lago BV, Mello FC, Martins RM. Prevalence of hepatitis B virus infection among tuberculosis patients with or without HIV in Goiânia City, Brazil. J Clin Virol 2012; 54: 327-331 [PMID: 22608842 DOI: 10.1016/j.jcv.2012.04.006]
18. de Castro L, do Brasil PE, Monteiro TP, Rolla VC. Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule. Int J Tuberc Lung Dis 2010; 14: 332-340 [PMID: 20132625]
19. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127: 1304-1311 [PMID: 15821209 DOI: 10.1378/chest.127.4.1304]
20. Nader LA, de Mattos AA, Picon PD, Bassanesi SL, De Mattos AZ, Pineiro Rodriguez M. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor? Ann Hepatol 2010; 9: 70-74 [PMID: 20308724]
21. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-1876 [PMID: 9620920 DOI: 10.1164/ajrccm.157.6.9711039]
22. Chien JY, Huang RM, Wang JY, Ruan SY, Chien YJ, Yu CJ, Yang PC. Hepatitis C virus infection increases hepatitis risk during antituberculosis treatment. Int J Tuberc Lung Dis 2010; 14: 616-621 [PMID: 20392356]
23. The National Collaborating Centre for Chronic Conditions. Tuberculosis (CG117). Clinical diagnosis and management of tuberculosis and measures for its prevention and control. 2011. Date last accessed: 2012 Sept 28. Available from: URL: http:// guidance.nice.org.uk/CG117
24. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330 [PMID: 8229110 DOI: 10.1016/0895-4356(93)90101-6]
25. Health Protection Agency Centre for Infections. Tuberculosis in London 2010. Annual report on tuberculosis surveillance in London. 2011. Date last accessed: 2012 Sept 28. Available from: URL: http://www.hpa.org.uk/webc/HPAwebFile/ HPAweb-C/1314346024986
26. Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, Harris R, Ushiro-Lumb I, Moreea S, Alam S, Thomas HC, Khan S, Watt B, Pugh RN, Ramaiah S, Jervis R, Hughes A, Singhal S, Cameron S, Carman WF, Foster GR. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: The prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010; 17: 327-335 [PMID:20002307 DOI: 10.1111/j.1365-2893.2009.01240.x]
27. Radziewicz H, Uebelhoer L, Bengsch B, Grakoui A. Memory CD8+ T cell differentiation in viral infection: A cell for all seasons. World J Gastroenterol 2007; 13: 4848-4857 [PMID: 17828816]
28. Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, Dockrell H, Pasvol G, Hill AV. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1998; 95: 270-275 [PMID: 9419365 DOI: 10.1073/pnas.95.1.270]
29. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952 [PMID: 17021358 DOI: 10.1164/rccm.200510-1666ST]
30. Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell DW, George PM, Molyneaux PL, Cooke GS, Burroughs AK, Lalvani A, Wickremasinghe M, Kon OM. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med 2012; 185: 653-659 [PMID: 22198973 DOI: 10.1164/rccm.201105-0850OC]